Eintrag weiter verarbeiten
The future role of monoclonal antibody therapy in childhood acute leukaemias
Gespeichert in:
Personen und Körperschaften: | , , |
---|---|
Titel: |
The future role of monoclonal antibody therapy in childhood acute leukaemias |
In: | British Journal of Haematology, 159, 2012, 1, S. 3-17 |
veröffentlicht: |
Wiley
|
Umfang: | 3-17 |
ISSN: |
1365-2141 0007-1048 |
DOI: | 10.1111/bjh.12002 |
Zusammenfassung: | <jats:title>Summary</jats:title><jats:p>Leukaemia is the single most common childhood malignancy. With modern treatment regimens, survival in acute lymphoblastic leukaemia (<jats:styled-content style="fixed-case">ALL</jats:styled-content>) approaches 90%. Only about 70% of children with acute myeloid leukaemia (<jats:styled-content style="fixed-case">AML</jats:styled-content>) achieve long term survival. Patients who relapse have a dismal prognosis. Novel therapeutic approaches are needed to improve treatment outcomes in newly‐diagnosed patients with a poor prognosis and for patients with relapsed/refractory disease that have limited treatment options. One promising approach in treating haematological malignancies has been the use of monoclonal antibodies to target cell surface antigens expressed on malignant cells. Most success with monoclonal antibody therapy in the treatment of haematological malignancies has come in the setting of adult <jats:styled-content style="fixed-case">B</jats:styled-content>‐cell non‐<jats:styled-content style="fixed-case">H</jats:styled-content>odgkin lymphoma with the addition of the anti‐<jats:styled-content style="fixed-case">CD</jats:styled-content>20 monoclonal antibody rituximab to standard treatment regimens. In order to further advance treatment of haematological malignancies, novel monoclonal antibodies continue to be developed that target a variety of cell surface antigens. Several antibodies continue to be investigated in childhood leukaemias. This review will discuss the development of monoclonal antibodies that target a variety of cell surface antigens for the treatment of childhood <jats:styled-content style="fixed-case">ALL</jats:styled-content> and the use of the anti‐<jats:styled-content style="fixed-case">CD</jats:styled-content>33 antibody gemtuzumab ozogamicin in the treatment of childhood <jats:styled-content style="fixed-case">AML</jats:styled-content>.</jats:p> |
Format: | E-Article |
Quelle: | Wiley (CrossRef) |
Sprache: | Englisch |